Abstract 2258P
Background
Currently, response to cancer treatment cannot be predicted upfront, hampering treatment efficacy. There is a need for effective biomarkers to select patients for optimal treatment. A promising predictive biomarker is response testing on patient-derived organoids (PDOs). For metastatic colorectal cancer (mCRC), it is unclear what drug screening method is optimal and if PDOs predict response for all treatment types.
Methods
Drug screens were performed by exposing 23 PDOs to a concentration range of systemic drugs for 5 days. The following standard mCRC treatments were evaluated: 5-fluorouracil (n = 6), oxaliplatin (n = 14) and irinotecan (n = 10). Drug sensitivity was measured by cell viability and quantified by calculating the area under the curve (AUC). We compared in vitro sensitivity to patient response, evaluated using progression-free survival (PFS) and % change in the size of target lesions on CT scans.
Results
Drug screen methods regarding medium composition (with/without N-acetylcysteine), combination treatment ratios and read-outs were optimized, as they impact the correlation with clinical response. Correlations were seen between PDO response (AUC) and patient response (% change) for all chemotherapies (Spearman r = 0.3-0.6, ns). PFS was evaluable for patients treated with oxaliplatin (n=14). Median PFS of patients with organoids classified as resistant to oxaliplatin-based treatment - based on AUC - was relevantly shorter than for organoids classified as sensitive (3.4 vs 10.1 months, log rank p = 0.07). PDOs from patients previously exposed to chemotherapy showed increased resistance to chemotherapy with a significantly higher AUC (median 0.9 vs 0.4, Mann-Whitney U p = 0.005).
Conclusions
After drug screen optimization, we show that PDO response correlates with patient response to commonly used systemic mCRC treatments. This suggests that PDOs can serve as a predictive biomarker and guide personalized cancer treatment. PDOs adequately reflect prior treatment effect, supporting their use for modeling mCRC. Our findings and optimized screening method will be validated in the ongoing OPTIC trial (NL61668.041.17), to facilitate implementation of PDOs in clinical treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Medical Center Utrecht.
Funding
HUB Organoids.
Disclosure
L. Valkenburg-van Iersel: Financial Interests, Advisory Role, Also travel/accommodations paid or reimbursed: Servier, Pierre Fabre; Financial Interests, Advisory Role: Roche, Amgen. M. Koopman: Financial Interests, Institutional, Advisory Board, advisory board and speaker: Pierre Fabre; Financial Interests, Institutional, Advisory Board: MSD, Bayer; Financial Interests, Institutional, Advisory Board, Advisory Board, speaker: Servier; Financial Interests, Institutional, Invited Speaker: Merck, BMS; Financial Interests, Institutional, Trial Chair: Servier; Financial Interests, Institutional, Research Grant: Servier, Roche, Bayer, Bristol Myers Squibb, Merck, Personal Genomics Diagnostics, Sirtex, Pierre Fabre; Financial Interests, Institutional, Funding: Pierre Fabre, Amgen, Nordic Pharma, Novartis, Merck, Servier, BMS; Non-Financial Interests, Leadership Role, vice-chair of DCCG: Dutch Colorectal Cancer Group; Non-Financial Interests, Advisory Role, Member of KWF scientific board: KWF; Non-Financial Interests, Other, ESMO faculty member for the Gastro-Intestinal Tumours – colorectal cancer: ESMO; Non-Financial Interests, Advisory Role, expert member of committee “regie op registers dure geneesmiddelen” ZINNL; Non-Financial Interests, Advisory Role, CRC expert on Kanker.nl platform for answering online CRC questions of CRC (non) patients: Patient representative organisation (Kanker.nl); Non-Financial Interests, Leadership Role, chair of RWD & DH working group: ESMO; Other, PI of the Dutch Prospective Colorectal Cancer Cohort study: PLCRC project. J.M.L. Roodhart: Financial Interests, Institutional, Advisory Board: Bayer, BMS, Merck-Serono, Pierre Fabre, Servier, Amgen; Financial Interests, Institutional, Funding: HUB Organoids, Cleara Biotech, BMS, Pierre Fabre, Servier; Financial Interests, Institutional, Member of Board of Directors: Foundation Hubrecht Organoid Biobank. All other authors have declared no conflicts of interest.
Resources from the same session
2252P - KRAS G12C inhibition using MRTX849: A novel radio-sensitizing partner
Presenter: Marina Milic
Session: Poster session 08
2253P - RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer
Presenter: Helen Adderley
Session: Poster session 08
2254P - Persisting RAS addiction: A therapeutic vulnerability in the context of KRAS G12C inhibitor resistance
Presenter: George Morrissey
Session: Poster session 08
2255P - Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers
Presenter: Biagio Ricciuti
Session: Poster session 08
2256P - The microenvironment of normal mucosa could predict recurrence in the stage II/III colorectal cancer: Multicenter, multiomics study
Presenter: Yeonghak Bang
Session: Poster session 08
2257P - Stereotactic body radiation therapy and atezolizumab combination: Results of the international multi-centre SABR-PDL1 phase II trial colorectal cohort
Presenter: Antonin Levy
Session: Poster session 08
2259P - An artificial neural network system to predict the fraction of type I polarized macrophage
Presenter: Tongji Xie
Session: Poster session 08
2260P - Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Presenter: Andrea Paccone
Session: Poster session 08
2261P - A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients
Presenter: Nadia Dandachi
Session: Poster session 08
2262P - Baseline-informed versus tumor-agnostic minimal residual disease (MRD) concordance study in patients with HER2+ gastroesophageal adenocarcinoma patients
Presenter: Pan Du
Session: Poster session 08